ACELYRIN (SLRN) Q2 2025 earnings summary

Executive summary

• Report covers the quarter ended June 30, 2025, following the completion of the ACELYRIN Merger in May 2025, which added lonigutamab to the development portfolio and strengthened the balance sheet.

• Focus remains on advancing TYK2 inhibitors (envudeucitinib and A-005) and integrating ACELYRIN operations.

• Completed enrollment in Phase 3 ONWARD trials for envudeucitinib in plaque psoriasis and Phase 2b LUMUS trial in SLE; topline data expected in 2026.

• No products are approved for sale; revenue is from collaboration and license agreements.

• Promoted Sanam Pangali to Chief Legal Officer and Corporate Secretary.

Financial highlights

• Net income for Q2 2025 was $59.3 million, compared to a net loss of $56.5 million in Q2 2024, driven by a $187.9 million gain on bargain purchase from the ACELYRIN Merger.

• Total revenue for the quarter was $2.7 million, primarily from collaboration agreements; six-month revenue was $20.1 million.

• Research and development expenses rose 124% year-over-year to $108.8 million for Q2 2025, reflecting increased clinical activity and integration costs.

• General and administrative expenses increased 355% year-over-year to $34.5 million, mainly due to ACELYRIN Merger transaction costs and higher headcount.

• Cash, cash equivalents, and marketable securities totaled $486.3 million as of June 30, 2025.

Outlook and guidance

• Existing liquidity is expected to fund operations for at least 12 months from the report date, with some guidance extending funding into 2027.

• Management anticipates continued substantial losses as clinical programs advance and integration of ACELYRIN continues.

• Research and development expenses are expected to decrease for the remainder of 2025.

• Additional capital will be needed to fund ongoing R&D and future operations.

• Participation planned in several major healthcare investor conferences in September 2025.